The company has launched Valganciclovir tablets, USP in the strength of 450 mg in the US market on December 15, 2014 and the product has been approved by the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE today.
Drug firm Dr Reddys Laboratories has launched generic anti-viral Valganciclovir tablets in the US market.
The company has launched Valganciclovir tablets, USP in the strength of 450 mg in the US market on December 15, 2014 and the product has been approved by the United States Food
and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE today.
The tablets are generic version of Roche's Valcyte tablets, it added. "The Valcyte tablets brand had US sales of approximately USD 440 million MAT for the most recent twelve months ending in October 2014 according to IMS health," Dr Reddy's said.
Shares of Dr Reddy's Laboratories were today trading at Rs 3,175.60 per scrip in the afternoon trade on the BSE, down 5.32 per cent from its previous close.
Dr Reddys Labs stock price
On December 10, 2014, Dr Reddys Laboratories closed at Rs 3142.05, down Rs 212.1, or 6.32 percent. The 52-week high of the share was Rs 3662.00 and the 52-week low was Rs 2250.00.
The company's trailing 12-month (TTM) EPS was at Rs 125.08 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 25.12. The latest book value of the company is Rs 547.59 per share. At current value, the price-to-book value of the company is 5.74.
Anda sedang membaca artikel tentang
Dr Reddy's launches generic anti-viral tablets in US market
Dengan url
http://kebugaranhidup.blogspot.com/2014/12/dr-reddys-launches-generic-anti-viral.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Dr Reddy's launches generic anti-viral tablets in US market
namun jangan lupa untuk meletakkan link
Dr Reddy's launches generic anti-viral tablets in US market
sebagai sumbernya
0 komentar:
Posting Komentar